Zofenil
- Name:
Zofenil
- Company:
A. Menarini Pharmaceuticals Ireland Ltd
- Active Ingredients:
- Legal Category:
Product subject to medical prescription which may be renewed (B)
Patient Information Leaflet Patient Information Leaflet last updated on medicines.ie: 25/07/19
(Click to Download)XPIL
PACKAGE LEAFLET: INFORMATION FOR THE USER
PACKAGE LEAFLET: INFORMATION FOR THE USER
1. WHAT ZOFENIL IS AND WHAT IT IS USED FOR
1. WHAT ZOFENIL IS AND WHAT IT IS USED FOR
2. WHAT YOU NEED TO KNOW BEFORE YOU TAKE ZOFENIL
2. WHAT YOU NEED TO KNOW BEFORE YOU TAKE ZOFENIL
3. HOW TO TAKE ZOFENIL
3. HOW TO TAKE ZOFENIL
4. POSSIBLE SIDE EFFECTS
4. POSSIBLE SIDE EFFECTS
5. HOW TO STORE ZOFENIL
5. HOW TO STORE ZOFENIL
6. CONTENTS OF THE PACK AND OTHER INFORMATION
6. CONTENTS OF THE PACK AND OTHER INFORMATION
Click on this link to Download PDF directly
A. Menarini Pharmaceuticals Ireland Ltd
Company Products
When a pharmaceutical company changes any document, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.
Updated on 25 July 2019 PIL
Reasons for updating
- Change to section 2 - what you need to know - warnings and precautions
- Change to section 2 - interactions with other medicines, food or drink
Updated on 3 August 2018 PIL
Reasons for updating
- Change to section 2 - what you need to know - contraindications
- Change to section 2 - what you need to know - warnings and precautions
- Change to section 2 - interactions with other medicines, food or drink
- Change to section 2 - excipient warnings
- Change to section 4 - possible side effects
- Change to section 5 - how to store or dispose
Updated on 3 August 2018 SmPC
Reasons for updating
- Change to section 4.2 - Posology and method of administration
- Change to section 4.3 - Contraindications
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
- Change to section 4.6 - Pregnancy and lactation
- Change to section 4.8 - Undesirable effects
- Change to section 5.2 - Pharmacokinetic properties
Legal category: Product subject to medical prescription which may be renewed (B)
Free text change information supplied by the pharmaceutical company
The SmPC was updated to implement the outcome of PSUSA on Captopril / Hydrochlorothiazide, applicable to the whole class of medicinal products containing ACE inhibitors.
The following amendments were made:
- update in line with the latest QRD template;
- addition of the standard statement on sodium content in the PL in accordance with the Annex to the EC guideline on excipients;
- addition of ‘Endocrine effects’ in section 4.8 of the SmPC as text alignment of a known class effect.
Updated on 12 May 2018 SmPC
Reasons for updating
- New SmPC for new product
Legal category: Product subject to medical prescription which may be renewed (B)
Updated on 16 December 2014 SmPC
Reasons for updating
- Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
- Change to section 4.6 - Pregnancy and lactation
- Change to section 4.8 - Undesirable effects
- Change to Section 4.8 – Undesirable effects - how to report a side effect
- Change to section 5.1 - Pharmacodynamic properties
- Change to section 6.6 - Special precautions for disposal and other handling
- Change to section 10 - Date of revision of the text
- Change to section 2 - Qualitative and quantitative composition
- Change to section 3 - Pharmaceutical form
- Change to section 4.2 - Posology and method of administration
- Change to section 4.3 - Contraindications
- Change to section 4.4 - Special warnings and precautions for use
Legal category: Product subject to medical prescription which may be renewed (B)
Free text change information supplied by the pharmaceutical company
Administrative amendments (to align to the current QRD template)
Sections 2, 3, 4.2, 4.4, 4.6, 4.8, 5.2, 6.6.
Section 4.3 Contraindications
New contra-indication added on the concomitant use with aliskiren-containing products in patients with diabetes mellitus or renal impairment.
Section 4.4 Special warnings and precautions
New warning added regarding the dual blockade of RAAS through the combined use of ACE-inhibitors, angiotensin II receptor blockers or aliskiren is not recommended,
Section 4.5 Interactions with other medicinal products and other forms of interaction
New interaction added under ‘Concomitant use not recommended’:
ACE-inhibitors, angiotensin II receptor blockers or aliskiren:
Section 4.8 Undesirable effects
Reporting of side-effects details added.
Section 5.1 Pharmacodynamic properties
Details of two studies added with details about the use of combination of an ACE-inhibitor with an angiotensin II receptor blocker.
Information added on a further study to test the benefit of adding aliskiren to a standard therapy of an ACE-inhibitor or an angiotensin II receptor blocker in patients with type 2 diabetes mellitus and chronic kidney disease, cardiovascular disease, or both.
Section 10 Date of revision of the text
Updated to November 2014
Updated on 16 December 2014 PIL
Reasons for updating
- New PIL for new product
Updated on 16 December 2014 SmPC
Reasons for updating
- New SmPC for new product
Legal category: Product subject to medical prescription which may be renewed (B)
Updated on 16 December 2014 PIL
Reasons for updating
- Change to warnings or special precautions for use
- Change of contraindications
- Change to drug interactions
- Change to date of revision
- Change to improve clarity and readability
- Addition of information on reporting a side effect.
Updated on 10 July 2013 PIL
Reasons for updating
- Change of inactive ingredient
- Change to date of revision
Updated on 9 July 2013 SmPC
Reasons for updating
- Change to section 6.5 - Nature and contents of container
Legal category: Product subject to medical prescription which may be renewed (B)
Free text change information supplied by the pharmaceutical company
New packaging material for the blister added - Aclar/Aluminium
Updated on 30 March 2010 SmPC
Reasons for updating
- Change to section 2 - Qualitative and quantitative composition
- Change to section 3 - Pharmaceutical form
- Change to section 4.3 - Contraindications
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
- Change to section 4.6 - Pregnancy and lactation
- Change to section 4.8 - Undesirable effects
- Change to section 9 - Date of renewal of authorisation
- Change to section 10 - Date of revision of the text
Legal category: Product subject to medical prescription which may be renewed (B)
Free text change information supplied by the pharmaceutical company
Main changes:
- Section 2 Qualitative and Quantative composition: reference added on excipients including lactose.
- Section 3 Pharmaceutical form: Zofenil 15 mg tablets – the tablet can be divided into equal halves.
- Section 4.3 Contraindications: Specify second and third trimester of pregnancy. Remove lactation period.
- Section 4.4 Special warnings and precautions for use: Further information added on hypotension and heart failure, anaphylactic reactions during desensitisation or after insect bites, angioedema, cough, hyperkalaemia, surgery/anaesthesia, aortic and mitral valve stenosis/hypertrophic cardiomyopathy, neutropenia/agranulocytosis, proteinuria. New information included on hepatic failure, diabetic patients, lithium, race, pregnancy and lactose.
- Section 4.5 Interactions: Further information added on potassium sparing diuretics or potassium supplements, diuretics (thiazide or loop diuretics),other antihypertensive agents, lithium, NSAIDs, sympathomimetics. New information added on gold, tricyclic antidepressants, barbiturates, procainamide, cytostatic or immunosuppressive agents, antidiabetics.
- Section 4.6 Pregnancy and lactation: Information updated. Use in first trimester of pregnancy not recommended, contraindicated during the second and third trimester. Not recommended during breastfeeding.
- Section 4.8 Undesirable effects: Section rewritten to add adverse reactions associated with ACE inhibitors therapy.
- Section 9 Date of first authorisation/renewal – updated.
- Section 10 Date of the revision of the text – updated.
Updated on 12 March 2010 PIL
Reasons for updating
- Change due to harmonisation of patient information leaflet
- Change due to user-testing of patient information
Updated on 22 December 2005 SmPC
Reasons for updating
- Change to section 6.5 - Nature and contents of container
Legal category: Product subject to medical prescription which may be renewed (B)
Updated on 27 June 2005 PIL
Reasons for updating
- Change of active ingredient
Updated on 23 September 2004 SmPC
Reasons for updating
- New SPC for new product
Legal category: Product subject to medical prescription which may be renewed (B)
Updated on 5 August 2004 PIL
Reasons for updating
- New PIL for new product